Clinical Benefit, Price of Cancer Drugs in United States and Europe: A Comparison Study
Researchers report on a study comparing the US cost and clinical benefit of recently approved cancer drugs with those in Europe.
Researchers report on a study comparing the US cost and clinical benefit of recently approved cancer drugs with those in Europe.
Survey also shows that Americans may be misinformed about alternative treatments for cancer.
Researchers determined that aggressive care at the end of life (EOL) leads to diminished quality of life, poor quality of care, and increased costs for patients with advanced lung cancer.
Results of an electronic survey of women with a history of stage 0-III breast cancer revealed patients’ preferences for including costs when discussing treatment options with their cancer care team.
A team from Oncology Hematology Care, in Cincinnati, Ohio, presented an outcomes report on their Oncology Care Model project at the 2018 ASCO Quality Care Symposium.
Money raised for cancer-related appeals is on the increase; but some money funds alternative therapies that have been discredited.
The American Society of Clinical Oncology hosted a roundtable to develop recommendations targeted at improving patients’ out-of-pocket costs for clinical trial participation.
Non-English speaking and uninsured patients with cancer may require additional support systems, such as referral to socioeconomic support, for best care.
In a systematic review, researchers explored the financial burden of treating grade 3 to 4 adverse events associated with melanoma and its treatment.
Use of opioids to manage cancer-related pain may have adverse effects of its own that can have a significant impact on healthcare use among patients with cancer.